NEW at NYT: The Democratic Party is facing a voter registration crisis in red, blue and battleground states alike — losing ground to the GOP everywhere. My deep dive into the numbers and what it reveals about the party's brand. Thread —> nytimes.com/2025/08/20/us/…

HHS says ‘the science speaks for itself’ on mRNA cuts. Some of the scientists it cites disagree Good piece from Max Bayer. endpoints.news/researchers-ci…

If you’ve ever wondered how Madison can build one luxury apartment building after another after another after another, here’s a big part of why:

…most embarrassing thing to happen so far

Pepperdine student journalists uncovered this:

For the past month, I’ve been working on a project to map out and document the work of one of the most prolific storefront sign painters in the US - this is Detroit’s Ron Signs

It's Anna Brown day at Endpoints, with three new stories. Her latest: a look at the US manufacturing commitments made by drugmakers in the last six months. At least $292B by her count! A useful marker to check back on in the coming months and years. endpoints.news/biopharma-has-…

A journalist for 24 years, this is probably the most important article I've ever published. We saw the famine in Gaza with our own eyes. Together with Yarden Michaeli. Yarden Michaeli ירדן מיכאלי يردين ميخائيلي haaretz.com/israel-news/20…

Endpoints: CDC staff won't serve as members of ACIP's new Covid-19 working group by Max Bayer Max Bayer bit.ly/4lHx2Si

A NYC-based schizophrenia drug developer could be one of the first biotech companies to test the IPO waters after six months of no US biotech listing debuts LB Pharmaceuticals is said to be days away from flipping its S-1, according to sources endpoints.news/lb-pharmaceuti…

Friday IPO scoop from Kyle LaHucik: LB Pharmaceuticals is working with Leerink and additional investments banks on a public filing that could come "in the coming days." The public market has been frozen solid this year for drugmakers. endpoints.news/lb-pharmaceuti…